TARGOVAX ASA NK -,10 Aktie

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, TARGOVAX ASA NK -,10 Aktie had revenue of €954.22K and net profit of -€41.3M

(EUR)	2022	YoY
Revenue	954.22K	-
Gross profit	954.22K	-
Net profit	-41.3M	322.70%
EBITDA	-9.32M	1.32%

Fundamentals

Metric	Value
Market capitalization	€11.95M
Number of shares	209.27M
52-week high/low	€0.17 - €0.0435
Dividends	No
Beta	1.86
P/E ratio	-29.50
PEG ratio	-1.51
P/B ratio	4.61
P/S ratio	0.00

Company profile

Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical trials for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen vaccines targeting mutant KRAS cancers. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.